Grossman Nicole L, Doros Gheorghe D, Fandino Nicolas, Fuhlbrigge Anne L, Pace Wilson D, Wechsler Michael E, Yawn Barbara P, Israel Elliot
a Lahey Hospital and Medical Center , Burlington , MA , USA.
b Harvard Clinical Research Institute , Boston , MA , USA.
J Asthma. 2019 Jul;56(7):704-710. doi: 10.1080/02770903.2018.1486855. Epub 2018 Oct 4.
Exacerbations account for much of the morbidity in asthma. In a large intervention study, we sought to test the hypothesis that a Black adult exacerbation-prone phenotype - a group of Black people with asthma who are at high risk of repeat exacerbation within one year - exists in asthma independent of clinical control.
We analyzed exacerbation risk factors in 536 self-identified Black Americans with asthma eligible for, or on, Step 3 National Asthma Education and Prevention Program (NAEPP) therapy who participated in a randomized 6-18 month trial of tiotropium versus long acting beta agonist as add-on therapy to inhaled corticosteroids. Exacerbations were defined as events treated by oral or systemic corticosteroids. Clinical control was assessed by a validated asthma control questionnaire (ACQ5).
Exacerbations became more likely with loss of clinical control. The mean baseline ACQs for exacerbators and non-exacerbators were 2.41 and 1.91, respectively (p < 0.001). The strongest independent factor associated with exacerbations across all ACQ levels was an exacerbation in the preceding year (adjusted OR 3.26; p < 0.001). The severity of prior exacerbations did not correlate with the likelihood of a future exacerbation. Lower baseline FEV1/FVC was also associated with increased risk of exacerbations.
Even though exacerbations increase with loss of clinical control, an exacerbation susceptibility phenotype exists in Black adults with asthma, independent of clinical control. This phenotype requires precision therapeutic targeting.
哮喘急性加重是导致哮喘患者发病的主要原因。在一项大型干预研究中,我们试图验证一个假设,即在哮喘患者中存在一种黑人成年急性加重易感性表型——指一组患有哮喘且在一年内有高复发急性加重风险的黑人——该表型与临床控制情况无关。
我们分析了536名自我认定为患有哮喘的美国黑人患者的急性加重风险因素,这些患者符合或正在接受美国国立哮喘教育与预防计划(NAEPP)第3步治疗,他们参与了一项为期6 - 18个月的随机试验,该试验比较了噻托溴铵与长效β受体激动剂作为吸入性糖皮质激素附加治疗的效果。急性加重被定义为需要口服或全身使用糖皮质激素治疗的事件。通过经过验证的哮喘控制问卷(ACQ5)评估临床控制情况。
临床控制不佳时,急性加重的可能性增加。急性加重者和非急性加重者的平均基线ACQ值分别为2.41和1.91(p < 0.001)。在所有ACQ水平上,与急性加重相关的最强独立因素是前一年发生过急性加重(校正比值比3.26;p < 0.001)。既往急性加重的严重程度与未来急性加重的可能性无关。较低的基线第一秒用力呼气容积/用力肺活量(FEV1/FVC)也与急性加重风险增加相关。
尽管急性加重会随着临床控制不佳而增加,但在患有哮喘的黑人成年人中存在一种与临床控制无关的急性加重易感性表型。这种表型需要精准的治疗靶点。